Skin

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 

Retrieved on: 
Wednesday, April 17, 2024
University, Radiation, BC Cancer Agency, Mouse, Cell, Carcinoma, Skin, Aks, UVB, Topical medication, University of British Columbia, IND, Patient, BC Cancer Research Centre, Neoplasm, Toxicity, Medication, Pharmaceutical industry

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world.

Key Points: 
  • VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world.
  • Treating AKs before the cells become cancerous and spread to other parts of the body is crucial.
  • For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy.
  • There is a real need for safer and more targeted topical therapies.”
    Derm-Biome expects to start topical formulation development this summer, with IND-enabling studies slated to begin in Q4.

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Retrieved on: 
Wednesday, April 17, 2024
Patient, Safety, Skin, Survival, CFT, CTT, Disease, Week, KIT, Temperature, Therapy, CSU, Pharmaceutical industry

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).

Key Points: 
  • HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).
  • Mast cell activation is known to be a critical driver in ColdU and SD.
  • In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria—chronic spontaneous urticaria (CSU).
  • "We are very grateful to all the investigators and patients who supported this trial," said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.

Zylö announces the creation and spinout of Atticus Pharma Inc.

Retrieved on: 
Wednesday, April 17, 2024
Foam, CVS, Walmart, Nature, Mouse, Kroger, Skin, Joint, Intelligence, Hair loss, Ulta Beauty

GREENVILLE, SC, April 17, 2024 (GLOBE NEWSWIRE) -- Zylö recently effected a spinout of Atticus Pharma Inc., whose mission is to unlock the value of the Z-pod® topical delivery platform in the pharmaceutical vertical.

Key Points: 
  • GREENVILLE, SC, April 17, 2024 (GLOBE NEWSWIRE) -- Zylö recently effected a spinout of Atticus Pharma Inc., whose mission is to unlock the value of the Z-pod® topical delivery platform in the pharmaceutical vertical.
  • Atticus is initially focused on the Joint Development Agreement with Yuva Biosciences, whereby Atticus has the worldwide, exclusive rights to YuvaBio’s Y200™, a terminalia chebula extract, for the treatment of alopecia-related conditions and for wound-healing.
  • Beyond this initial focus on Y200-loaded Z-pods, Atticus is looking to in-license other programs, either from Zylö or from other biopharma entities.
  • Scott Pancoast, CEO + founder of Zylö and executive chairman of Atticus, stated, "By focusing on the biopharma applications of the Z-pod drug-delivery platform, Atticus can be a real force in the topical drug arena and can drive significant value for its shareholders.”

Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology

Retrieved on: 
Tuesday, April 16, 2024
NESS, Society, Inflammation, Safety, Skin, Ichthyosis, Abstract, TRPV3, Keratoderma, Pharmaceutical industry

NESS ZIONA, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic skin diseases, today announced two abstracts reporting results for its novel TRPV3 inhibitors, KM-001(topical) and KM-023 (oral), have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.

Key Points: 
  • TRPV3 plays a central role in skin disease as it regulates proliferation, differentiation and barrier function of human skin.
  • KM-001 and KM-023 are specific and selective TRPV3 inhibitors that address both molecular and local damage to the skin by regulating Ca²⁺ influx into the cell, thereby reconstructing the skin barrier and reducing inflammation.
  • Kamari is currently developing KM-001 for the treatment of palmoplantar keratoderma and KM-023 for the treatment of Olmstead syndrome, severe keratoderma and Ichthyosis.
  • The details of the presentations are as follows:
    Title: Novel TRPV3 inhibitors developed for the treatment of palmoplantar keratodermas, demonstrate safety and efficacy in preclinical models

VANTAGE EXPANDS TAURATE MANUFACTURING CAPABILITIES IN GERMANY TO MEET GROWING CONSUMER MARKET DEMAND FOR MILD SURFACTANTS

Retrieved on: 
Monday, April 15, 2024
Skin, Certification, Steam, Scalp, CO2, DIN, Fine chemical

The expansion will meet customer demand and anticipated market growth in consumer-focused end markets such as personal care, laundry and household, industrial and institutional (HI&I).

Key Points: 
  • The expansion will meet customer demand and anticipated market growth in consumer-focused end markets such as personal care, laundry and household, industrial and institutional (HI&I).
  • Vantage is specifically expanding its METAUPON* NMT (N-Methyl Taurine) capacity to target demand in the personal care market.
  • Vantage Leuna is the company’s largest manufacturing site in the Europe, Middle East & Africa (EMEA) region and became part of Vantage in 2019.
  • The site also manufactures specialty surfactants and intermediates that support our consumer and industrial business divisions.

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, April 12, 2024
UCLA, Congress, Sale, European Patent Office, Rutgers University, Chronic obstructive pulmonary disease, Outline of health sciences, Alopecia areata, Eosinophilic bronchitis, Safety, Skin, Drug development, European Patent Convention, Research, EASI, MD, Trial of the century, COPD, KOL, ADS, DHODH, Patent, Data, Patient, Liver, Dupilumab, Translational medicine, International Examiner, Harvard Medical School, ASLN, TREK, AA, Associate, Clinical trial, Emergency medicine, EPO, SAN, Contract research organization, Pharmaceutical industry

Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.

Key Points: 
  • Cash used in operations for the fourth quarter of 2023 was $7.6 million compared to $12.0 million in the same period in 2022.
  • Research and development expenses were $9.6 million in the fourth quarter of 2023 compared to $10.7 million in the fourth quarter of 2022.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2023 compared to $2.7 million in the fourth quarter of 2022.
  • Net loss attributable to stockholders for the fourth quarter of 2023 was $13.5 million compared to a net loss of $14.5 million for the fourth quarter of 2022.

Carmell Announces Successful Closing of $3.0 Million Private Placement

Retrieved on: 
Thursday, April 11, 2024
Sale, Skin, Private, Private placement

PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “Private Placement”).

Key Points: 
  • PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “Private Placement”).
  • The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses.
  • The Company issued and sold an aggregate amount of 1,331,452 shares of its common stock upon the closing of the Private Placement at a price of $2.88 per share for the Company’s Chief Executive Officer (which was the closing sale price of the Company’s common stock on the Nasdaq Capital Market on April 3, 2024) and at a price of $2.25 per share for all other investors in the Private Placement.
  • Following the closing of the Private Placement, Carmell will have approximately 20.58 million shares of common stock outstanding.

32 Leading Brands Announce Exclusive Teacher Offers for National Teacher Appreciation Week

Retrieved on: 
Thursday, May 2, 2024
Software, Online Retail, Consumer, Electronic Commerce, Technology, Primary, Secondary, Digital Marketing, Education, Retail, Other Consumer, Marketing, Communications, Tiny Love, Clinique, Maytag, CMO, PLUS, L.L.Bean, KitchenAid, Skin, Teaching, XR, FIVE, Commerce, Cosmetics, Unity Technologies, Teacher, Pizza Hut, UGG, ThriftBooks, Dorel Industries, Learning, MAC, Aveda, Holland America Line, MAC Cosmetics, FREE, Travel, Tarte Cosmetics, Student, Evenflo, Beauty, Tutoring

SheerID, the global leader in identity verification for commerce, is proud to partner with over 32 brands in 8 retail categories to provide exclusive discounts for millions of educators during National Teacher Appreciation Week.

Key Points: 
  • SheerID, the global leader in identity verification for commerce, is proud to partner with over 32 brands in 8 retail categories to provide exclusive discounts for millions of educators during National Teacher Appreciation Week.
  • "Personalized and exclusive offers are a powerful way for brands to honor and thank teachers for the important work they do," stated Sai Koppala, CMO of SheerID.
  • Pizza Hut : Unlock exclusive perks at Pizza Hut during Teacher Appreciation Month!
  • Members must be signed up for Teachers' Circle before May 6 to receive Teacher Appreciation Week rewards.

28 Leading Brands Unveil Exclusive Discounts for National Nurses Week

Retrieved on: 
Thursday, May 2, 2024
Nursing, Data Management, Online Retail, Technology, Health, Fashion, Security, Cosmetics, Retail, Software, Home Goods, Tiny Love, Clinique, Maytag, CMO, PLUS, Critical care, L.L.Bean, THANK, KitchenAid, Safety, Skin, Travel, Codecademy, Commerce, Health care, Aveda, Ashley Furniture Industries, Military personnel, UGG, Dorel Industries, Alterra Mountain Company, MAC, Holland America Line, MAC Cosmetics, Purple, Health professional, The North Face, Tarte Cosmetics, Student, Evenflo

In an ongoing effort to honor the critical contributions of healthcare professionals, SheerID, the global leader in identity verification for commerce, has once again partnered with 28 leading brands to provide exclusive discounts during National Nurses Week.

Key Points: 
  • In an ongoing effort to honor the critical contributions of healthcare professionals, SheerID, the global leader in identity verification for commerce, has once again partnered with 28 leading brands to provide exclusive discounts during National Nurses Week.
  • “SheerID is delighted to continue our partnerships with brands that understand the importance of these frontline healthcare professionals,” expressed Sai Koppala, CMO of SheerID.
  • Burton Snowboards : Nurses can score up to 50% off select softgoods and up to 40% select hardgoods.
  • tarte cosmetics : tarte cosmetics honors healthcare heroes with an exclusive 40% discount on all products on tarte.com, year-round.

Kerecis to Provide Multiple Updates on its Medical-Fish-Skin Technology at the European Wound Management Association Meeting

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Surgery, Diabetes, Health, Medical Supplies, Use, Skin, Abstract, Excellence, Dicarboxylic acid, Cost, European Wound Management Association, Multimedia, Human, Complex, General surgery, EWMA, Fixation (psychology), NPWT, User experience, Dietary supplement

The company will also host a medical education event on the utilization of fish skin grafts on Wednesday, May 1.

Key Points: 
  • The company will also host a medical education event on the utilization of fish skin grafts on Wednesday, May 1.
  • Finally, Kerecis’ founder and CEO will summarize the company’s journey at the EWMA Innovation Forum Thursday, May 2.
  • Kerecis will be the subject of the following events at the conference:
    Intact Fish Skin for Chronic Wound Care – Dr. John Lantis, chair.
  • Thursday, May 2, 4 to 5 p.m. in the South Gallery Room 8-9-10
    Fish Skin for Wound Management: Are There Advantages?